SAM005
Charcot-Marie-Tooth Disease type 1A (CMT)
Pre-clinicalActive
Key Facts
Indication
Charcot-Marie-Tooth Disease type 1A (CMT)
Phase
Pre-clinical
Status
Active
Company
About Samsara Therapeutics
Samsara Therapeutics is a private, pre-clinical biotech pioneering a novel approach to treating neurodegenerative diseases through pharmacological activation of autophagy. The company has built a phenotypic screening platform using patient-derived iPSCs to discover and optimize small molecule autophagy activators, with a pipeline targeting ALS, Parkinson's, and CMT1A. Backed by a $25M Series A led by Apollo Health Ventures and endorsements from major patient advocacy foundations, Samsara is advancing multiple programs toward IND-enabling studies.
View full company profileTherapeutic Areas
Other Charcot-Marie-Tooth Disease type 1A (CMT) Drugs
| Drug | Company | Phase |
|---|---|---|
| SAM0022 | Samsara Therapeutics | Pre-clinical |